PLAYSTUDIOS INC (MYPS)

US72815G1085 - Common Stock

1.73  +0.01 (+0.58%)

After market: 1.73 0 (0%)

Fundamental Rating

4

Taking everything into account, MYPS scores 4 out of 10 in our fundamental rating. MYPS was compared to 72 industry peers in the Entertainment industry. MYPS has a great financial health rating, but its profitability evaluates not so good. MYPS has a valuation in line with the averages, but it does not seem to be growing.



3

1. Profitability

1.1 Basic Checks

In the past year MYPS has reported negative net income.
In the past year MYPS had a positive cash flow from operations.
In multiple years MYPS reported negative net income over the last 5 years.
Each year in the past 5 years MYPS had a positive operating cash flow.

1.2 Ratios

The Return On Assets of MYPS (-7.91%) is worse than 63.64% of its industry peers.
MYPS has a Return On Equity (-9.86%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -7.91%
ROE -9.86%
ROIC N/A
ROA(3y)-2.38%
ROA(5y)3.21%
ROE(3y)-3.03%
ROE(5y)4.23%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

MYPS has a Gross Margin of 75.11%. This is amongst the best in the industry. MYPS outperforms 89.39% of its industry peers.
MYPS's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for MYPS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 75.11%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.29%
GM growth 5Y2.64%

8

2. Health

2.1 Basic Checks

MYPS does not have a ROIC to compare to the WACC, probably because it is not profitable.
MYPS has more shares outstanding than it did 1 year ago.
MYPS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

MYPS has an Altman-Z score of 3.18. This indicates that MYPS is financially healthy and has little risk of bankruptcy at the moment.
MYPS has a better Altman-Z score (3.18) than 81.82% of its industry peers.
There is no outstanding debt for MYPS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 3.18
ROIC/WACCN/A
WACC9.43%

2.3 Liquidity

MYPS has a Current Ratio of 4.16. This indicates that MYPS is financially healthy and has no problem in meeting its short term obligations.
MYPS has a better Current ratio (4.16) than 90.91% of its industry peers.
MYPS has a Quick Ratio of 4.16. This indicates that MYPS is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of MYPS (4.16) is better than 90.91% of its industry peers.
Industry RankSector Rank
Current Ratio 4.16
Quick Ratio 4.16

3

3. Growth

3.1 Past

The earnings per share for MYPS have decreased strongly by -850.00% in the last year.
Looking at the last year, MYPS shows a decrease in Revenue. The Revenue has decreased by -4.60% in the last year.
The Revenue has been growing by 9.72% on average over the past years. This is quite good.
EPS 1Y (TTM)-850%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-166.67%
Revenue 1Y (TTM)-4.6%
Revenue growth 3Y4.83%
Revenue growth 5Y9.72%
Sales Q2Q%-6.1%

3.2 Future

Based on estimates for the next years, MYPS will show a very strong growth in Earnings Per Share. The EPS will grow by 37.60% on average per year.
Based on estimates for the next years, MYPS will show a decrease in Revenue. The Revenue will decrease by -5.25% on average per year.
EPS Next Y12.18%
EPS Next 2Y49.92%
EPS Next 3Y37.6%
EPS Next 5YN/A
Revenue Next Year-6.39%
Revenue Next 2Y-6.1%
Revenue Next 3Y-4.23%
Revenue Next 5Y-5.25%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MYPS. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 46.56, the valuation of MYPS can be described as expensive.
Based on the Price/Forward Earnings ratio, MYPS is valued a bit cheaper than the industry average as 60.61% of the companies are valued more expensively.
MYPS is valuated expensively when we compare the Price/Forward Earnings ratio to 23.53, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 46.56

4.2 Price Multiples

92.42% of the companies in the same industry are more expensive than MYPS, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of MYPS indicates a rather cheap valuation: MYPS is cheaper than 90.91% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 10.68
EV/EBITDA 2.77

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
MYPS's earnings are expected to grow with 37.60% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y49.92%
EPS Next 3Y37.6%

0

5. Dividend

5.1 Amount

No dividends for MYPS!.
Industry RankSector Rank
Dividend Yield N/A

PLAYSTUDIOS INC

NASDAQ:MYPS (1/14/2025, 8:00:01 PM)

After market: 1.73 0 (0%)

1.73

+0.01 (+0.58%)

Chartmill FA Rating
GICS SectorCommunication Services
GICS IndustryGroupMedia & Entertainment
GICS IndustryEntertainment
Earnings (Last)11-04 2024-11-04/amc
Earnings (Next)N/A N/A
Inst Owners38.54%
Inst Owner Change0.01%
Ins Owners3.56%
Ins Owner Change1.11%
Market Cap215.70M
Analysts77.14
Price Target3.57 (106.36%)
Short Float %0.69%
Short Ratio2.45
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-12.03%
Min EPS beat(2)-41.78%
Max EPS beat(2)17.72%
EPS beat(4)2
Avg EPS beat(4)-152.93%
Min EPS beat(4)-687.67%
Max EPS beat(4)100%
EPS beat(8)6
Avg EPS beat(8)-37.43%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.75%
Min Revenue beat(2)-5.33%
Max Revenue beat(2)1.83%
Revenue beat(4)3
Avg Revenue beat(4)-0.64%
Min Revenue beat(4)-5.33%
Max Revenue beat(4)1.83%
Revenue beat(8)5
Avg Revenue beat(8)1.26%
Revenue beat(12)7
Avg Revenue beat(12)0.76%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-7.89%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-566.67%
EPS NY rev (1m)0%
EPS NY rev (3m)-137.26%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-18.68%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.02%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 46.56
P/S 0.72
P/FCF 10.68
P/OCF 4.36
P/B 0.81
P/tB 1.91
EV/EBITDA 2.77
EPS(TTM)-0.19
EYN/A
EPS(NY)0.04
Fwd EY2.15%
FCF(TTM)0.16
FCFY9.36%
OCF(TTM)0.4
OCFY22.92%
SpS2.4
BVpS2.13
TBVpS0.91
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.91%
ROE -9.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 75.11%
FCFM 6.76%
ROA(3y)-2.38%
ROA(5y)3.21%
ROE(3y)-3.03%
ROE(5y)4.23%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.29%
GM growth 5Y2.64%
F-Score5
Asset Turnover0.9
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 63.07%
Cap/Sales 9.79%
Interest Coverage N/A
Cash Conversion 123.79%
Profit Quality N/A
Current Ratio 4.16
Quick Ratio 4.16
Altman-Z 3.18
F-Score5
WACC9.43%
ROIC/WACCN/A
Cap/Depr(3y)104.96%
Cap/Depr(5y)107.42%
Cap/Sales(3y)12.06%
Cap/Sales(5y)11.35%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-850%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-166.67%
EPS Next Y12.18%
EPS Next 2Y49.92%
EPS Next 3Y37.6%
EPS Next 5YN/A
Revenue 1Y (TTM)-4.6%
Revenue growth 3Y4.83%
Revenue growth 5Y9.72%
Sales Q2Q%-6.1%
Revenue Next Year-6.39%
Revenue Next 2Y-6.1%
Revenue Next 3Y-4.23%
Revenue Next 5Y-5.25%
EBIT growth 1Y-108.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year592.34%
EBIT Next 3Y98.07%
EBIT Next 5Y50.81%
FCF growth 1Y1009.73%
FCF growth 3Y-3.46%
FCF growth 5Y9.34%
OCF growth 1Y11.49%
OCF growth 3Y2.24%
OCF growth 5Y7.09%